Afinitor
Afinitor

34
Helps with the Regulating key cell signaling pathways.


Ingredient
Availability
In Stock
Delivery Time
Airmail (14-21 days) | Trackable (5-9 days)
Shipped in a discreet, unmarked envelope with all required documents enclosed.

Product Sheet

Active Ingredient(s)
Everolimus
Reference Brand
Everolimus
Product Origin
Generic Alternative
Reference Manufacturer
Novartis
Product Form
Tablet, Tablet for Oral Suspension
Regulatory Classification
Rx
Primary Category
Oncology Support
Product Category
mTOR Inhibitor
Pharmacological Class
Antineoplastic
Manufacturer Description
Designed for renal and breast cancer to target malignant cell growth and support oncology management.
Mechanism of Action
Everolimus binds to the intracellular protein FKBP-12, inhibiting the mTOR complex 1. This blockade prevents cell cycle progression, angiogenesis, and tumor cell metabolism, effectively slowing the spread of certain cancers.
Route of Administration
Oral
Onset Time
4–8 weeks
Duration
30 hours (half-life)
Contraindications
Hypersensitivity to everolimus, Hypersensitivity to sirolimus
Severe Adverse Events
Non-infectious pneumonitis, Renal failure, Serious opportunistic infections — requires immediate medical attention
Common Side Effects
Stomatitis, Fatigue, Nausea
Uncommon Side Effects
Anemia, Hyperglycemia, Rash
Drug Interactions
Grapefruit, Ketoconazole, Rifampin, St. John's Wort, Alcohol
Pregnancy Safety Warnings
FDA Category D: High risk of fetal harm. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy established in pediatric patients for TSC-related tumors.
Storage Guidelines
Store at room temperature and protect from light.
Related Products
Zortress, Rapamune
Information related to Afinitor is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
Categories
How to access Nicotine Cessation Drugs - Zyban Generic